The suppression of premature termination codons and the repair of splicing mutations in CFTR

Area of Science:

• Genetics and Molecular Biology
• Pharmacology and Drug Development
• Medical Genetics

Background:

• Premature termination codons (PTC) result from nucleotide substitutions, leading to truncated proteins and transcript degradation via nonsense-mediated decay (NMD).
• Splicing mutations disrupt normal RNA processing, often causing open reading frame disruption and NMD activation.
• Cystic Fibrosis (CF) is a genetic disorder frequently caused by these types of mutations.

Purpose of the Study:

• To review recent therapeutic advancements for CF patients with nonsense or splicing mutations.
• To highlight strategies that aim to restore full-length functional proteins.
• To discuss the potential of readthrough compounds and antisense oligonucleotides in CF treatment.

Main Methods:

• Review of current literature on therapeutic strategies for PTC and splicing mutations in CF.
• Analysis of the mechanisms of action for readthrough compounds and antisense oligonucleotides.
• Focus on recent developments and their potential clinical applications.

Main Results:

• Readthrough compounds promote the incorporation of near-cognate amino-acyl-tRNA, potentially restoring protein function.
• Antisense oligonucleotides can be chemically modified to target and correct aberrant splicing.
• Both approaches offer potential pathways to mitigate the effects of specific CF-causing mutations.

Conclusions:

• Therapeutic strategies targeting premature termination codons and splicing mutations are advancing.
• Readthrough compounds and antisense oligonucleotides represent promising avenues for improving health in CF patients.
• Further research and development are crucial for clinical translation and patient benefit.